Fang and colleagues report the safety and clinical activity of hypoxia-responsive carcinoembryonic antigen (CEA)-targeted chimeric antigen receptor T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion in a phase 1 trial.
- Yang Gao
- Jie Li
- Weijia Fang